GSK offers concessions ahead of planned venture with Pfizer

pharmafile | June 21, 2019 | News story | Medical Communications, Sales and Marketing GSK, Pfizer, pharma 

The European Commission has said that GlaxoSmithKline has offered concessions to address concerns relating to the British multinational’s planned joint venture with Pfizer’s consumer health business.

The EU competition enforcer will make its decision as to whether to accept the proposed merger, demand further concessions or open a full-scale investigation into the deal, by 10 July.

The concessions come as GSK began to sell off some of its consumer healthcare products ahead of the folding of its consumer healthcare brands into a joint venture with Pfizer. The deal was announced in December last year.

The agreement will see the two firms form a “premier global consumer healthcare company.” Pfizer will own 32% of the new consumer healthcare business. GSK will own the rest.

Louis Goss

Related Content

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

GSK and Save the Children extend partnership for unvaccinated children

GSK and Save the Children have announced that they will be renewing their partnership for …

Latest content